发明授权
EP0854870B1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY
失效
与癌症REMME SANTANDER和作用CYTOKININHIBIERENDER取代咪唑
- 专利标题： SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY
- 专利标题（中）： 与癌症REMME SANTANDER和作用CYTOKININHIBIERENDER取代咪唑
-
申请号： EP96937654.0申请日： 1996-10-02
-
公开(公告)号： EP0854870B1公开(公告)日： 2009-06-10
- 发明人: SELNICK, Harold, G. , CLAREMON, David, A. , LIVERTON, Nigel, J.
- 申请人： Merck & Co., Inc.
- 申请人地址： 126 East Lincoln Avenue Rahway, New Jersey 07065 US
- 专利权人： Merck & Co., Inc.
- 当前专利权人： Merck & Co., Inc.
- 当前专利权人地址： 126 East Lincoln Avenue Rahway, New Jersey 07065 US
- 代理机构： Horgan, James Michael Frederic
- 优先权： US5059P 19951006; US5063P 19951006; GB9602975 19960213; GB9602907 19960213
- 国际公布： WO1997012876 19970410
- 主分类号： C07D401/14
- IPC分类号： C07D401/14 ; A61K31/415 ; A61K31/44 ; A61K31/445 ; C07D417/14
摘要：
Compounds represented by formula (I), are disclosed. AR represents an aromatic group containing 6-10 atoms; and (a) represents a 4 to 10 membered non-aromatic heterocycle containing at least one N atom, and optionally containing 1-2 additional N atoms and 0-1 O or S atom. A pharmaceutical composition is also included. Methods of treating cancer and cytokine mediated diseases are also included.
公开/授权文献
信息查询
